Marker Therapeutics Inc (MRKR)

[Gatta-git-it]

A neutral thought.... M&A pro forma analysis is repeatedly done and reported within BP.
Re: MARKER pipeline...
For each C/trial.
Population: How many desease impacted domestically?
What is estimated P rate?
Revenue: What is estimated revenue per each full treatment based on P rate?
Expense: Direct cost of product?
Ancillary cost and amortization of research cost?
Profit margin per patient, cumulative per year and 5 year forward scan?

Wouldn't it be great if we had one talented person who could take a crack at this? BP has. It becomes a part of their constant " acquisition process." We do have some data on PC population and cost estimate.

Summary: We know our excellent management team. We know much of the science. We are stymied at the low valuation of share price. We believe that some algorithm trades likely are taking place. What we would benefit from is a multi Pro forma.
Of course, in my opinion, only.